|
1. Biologie
|
|
|
|
2.4 Etiologie - Portables, ondes e-m
|
|
|
|
3.1 Tabac
|
|
|
|
|
|
|
|
3.1.1 Tabac - e-cigs
|
|
|
|
|
|
|
FDA issues sweeping regulations for e-cigarettes for first time [STAT]
|
|
|
|
|
|
The
499-page final rule would require regulatory reviews for electronic
cigarettes, cigars, and other products that went on sale after Feb. 15,
2007, unless the manufacturers can prove to FDA that they’re
“substantially equivalent” to products that were already being sold or
that there is some other reason they should be exempt.
|
|
|
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
5. Traitements
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.2 Pharma
|
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
Regulating Precision Medicine: Capacity vs. Overreach [RAPS]
|
|
|
|
|
|
The
researchers point to the quagmire at hand for FDA and others, noting
that on the one hand, regulators need to ensure the capacity of existing
regulatory structures is adequate to respond to emerging genomic
sequencing, gene editing and other technologies, but on the other hand,
“regulatory overlap and confusion,” is a risk, as is “a veritable
‘regulatory soup’ that could drown the promised advances in precision
medicine.”
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
|
5.9 AACR
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
|
6.1 Observation
|
|
|
|
|
6.10 Politiques
|
|
|
|
|
|
6.11 Patients
|
|
|
|
6.4 Médico-éco
|
|
|
|
6.5 Médecines alternatives
|
|
|
|
6.6 Publications
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
|
6.9 Controverses
|
|
|
|
|
|
|
|
|